171 related articles for article (PubMed ID: 9874107)
1. Towards an AIDS vaccine: the role of primate models.
Nathanson N
Int J STD AIDS; 1998; 9 Suppl 1():3-7. PubMed ID: 9874107
[TBL] [Abstract][Full Text] [Related]
2. Towards an AIDS vaccine: the role of nonhuman primates.
Nathanson N; Mathieson BJ
J Med Primatol; 1999; 28(4-5):146-53. PubMed ID: 10593479
[TBL] [Abstract][Full Text] [Related]
3. Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.
Le Grand R; Dereuddre-Bosquet N; Dispinseri S; Gosse L; Desjardins D; Shen X; Tolazzi M; Ochsenbauer C; Saidi H; Tomaras G; Prague M; Barnett SW; Thiebaut R; Cope A; Scarlatti G; Shattock RJ
J Virol; 2016 Jun; 90(11):5315-5328. PubMed ID: 27009957
[TBL] [Abstract][Full Text] [Related]
4. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
[TBL] [Abstract][Full Text] [Related]
5. Mucosal Vaccination for Prevention of HIV Infection and AIDS.
Aldovini A
Curr HIV Res; 2016; 14(3):247-59. PubMed ID: 26957199
[TBL] [Abstract][Full Text] [Related]
6. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
[TBL] [Abstract][Full Text] [Related]
7. Nonhuman primate models for HIV vaccine development.
Letvin NL
Immunodefic Rev; 1992; 3(3):247-60. PubMed ID: 1510838
[TBL] [Abstract][Full Text] [Related]
8. Determining the immune mechanisms of protection from AIDS: correlates of immunity and the development of syngeneic macaques.
Kent SJ; Ada GL; Hayes E; Lewis IM
Immunol Rev; 2001 Oct; 183():94-108. PubMed ID: 11782250
[TBL] [Abstract][Full Text] [Related]
9. Antigenic requirement for Gag in a vaccine that protects against high-dose mucosal challenge with simian immunodeficiency virus.
Schell JB; Bahl K; Folta-Stogniew E; Rose N; Buonocore L; Marx PA; Gambhira R; Rose JK
Virology; 2015 Feb; 476():405-412. PubMed ID: 25591175
[TBL] [Abstract][Full Text] [Related]
10. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection.
Mooij P; van der Kolk M; Bogers WM; ten Haaft PJ; Van Der Meide P; Almond N; Stott J; Deschamps M; Labbe D; Momin P; Voss G; Von Hoegen P; Bruck C; Heeney JL
AIDS; 1998 Mar; 12(5):F15-22. PubMed ID: 9543435
[TBL] [Abstract][Full Text] [Related]
11. Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.
Mooij P; Nieuwenhuis IG; Knoop CJ; Doms RW; Bogers WM; Ten Haaft PJ; Niphuis H; Koornstra W; Bieler K; Köstler J; Morein B; Cafaro A; Ensoli B; Wagner R; Heeney JL
J Virol; 2004 Apr; 78(7):3333-42. PubMed ID: 15016855
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.
Chea LS; Amara RR
Expert Rev Vaccines; 2017 Oct; 16(10):973-985. PubMed ID: 28838267
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
[TBL] [Abstract][Full Text] [Related]
14. Prospects for vaccine protection against HIV-1 infection and AIDS.
Letvin NL; Barouch DH; Montefiori DC
Annu Rev Immunol; 2002; 20():73-99. PubMed ID: 11861598
[TBL] [Abstract][Full Text] [Related]
15. Protection of SIVmac-infected macaque monkeys against superinfection by a simian immunodeficiency virus expressing envelope glycoproteins of HIV type 1.
Dunn CS; Hurtrel B; Beyer C; Gloeckler L; Ledger TN; Moog C; Kieny MP; Mehtali M; Schmitt D; Gut JP; Kirn A; Aubertin AM
AIDS Res Hum Retroviruses; 1997 Jul; 13(11):913-22. PubMed ID: 9223407
[TBL] [Abstract][Full Text] [Related]
16. Towards an HIV-1 vaccine: lessons from studies in macaque models.
Hulskotte EG; Geretti AM; Osterhaus AD
Vaccine; 1998; 16(9-10):904-15. PubMed ID: 9682336
[TBL] [Abstract][Full Text] [Related]
17. Tackling HIV and AIDS: contributions by non-human primate models.
Van Rompay KKA
Lab Anim (NY); 2017 May; 46(6):259-270. PubMed ID: 28530684
[TBL] [Abstract][Full Text] [Related]
18. Is an HIV vaccine possible?
Wilson NA; Watkins DI
Braz J Infect Dis; 2009 Aug; 13(4):304-10. PubMed ID: 20231996
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of primate models for AIDS.
Haigwood NL
AIDS Rev; 2004; 6(4):187-98. PubMed ID: 15700617
[TBL] [Abstract][Full Text] [Related]
20. Fc receptor but not complement binding is important in antibody protection against HIV.
Hessell AJ; Hangartner L; Hunter M; Havenith CE; Beurskens FJ; Bakker JM; Lanigan CM; Landucci G; Forthal DN; Parren PW; Marx PA; Burton DR
Nature; 2007 Sep; 449(7158):101-4. PubMed ID: 17805298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
